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6-thioguanine therapy in Crohn's disease?Dear Sir,
With great interest, we have read the updated ECCO
consensus on the treatment of Crohn's disease.1 Being highly
interested in research on the clinical use of thiopurines, we
feel that several additional commentsmay give opportunity to
a more balanced, evidence-based conclusion on the discarded
use of 6-thioguanine as an alternative thiopurine.
Firstly, the authors state that 6-thioguanine is the active
metabolite of azathioprine and mercaptopurine. The drug 6-
thioguanine has no pharmacological activity itself but needs to
be metabolised to exert its immunomodulatory effects. The
pharmacologically active anti-inflammatory metabolites of all
clinically used thiopurines (azathioprine,mercaptopurine and6-
thioguanine) are believed to be the 6-thioguanine nucleotides.
These endmetabolites cannot be administered as a drug itself.
Secondly, the consensus concludes that a high frequency of
6-thioguanine induced liver abnormalities has been reported,
nodular regenerative hyperplasia (NRH) of the liver in
particular. This holds true for a few studies using relatively
high dosages (more than 25 mg of 6-thioguanine per day).2,3
Other studies, including those using approximately 20 mg
daily, did not demonstrate an excessive increased risk of
developing NRH.4,5 Moreover, the references used in the ECCO
consensus do not provide a representative overview of the
available literature. One describes a case-report, two concern
data from the same research group using high-dose 6-
thioguanine, another merely describes the efficacy instead
of hepatotoxicity, and an additional reference provides data
on the incidence of NRH during therapy with 40 mg 6-
thioguanine daily. The more reassuring and encouraging
data on the development of NRH during use of approximately
20 mg of 6-thioguanine per day are lacking in this consensus4,
including a series of about 100 liver biopsy specimens
presented at the ECCO meeting in 2010, demonstrating a
prevalence of NRH of approximately 4% during long-term 6-
thioguanine therapy.6
Finally, the authors state that NRH is an irreversible cause
of portal hypertension. The reversibility of NRH and its
potential complication of portal hypertension has been
studied by measurement of the hepatic venous pressure
gradient, but not by long-term, prospective follow-up of
series of patients. It has been demonstrated that discontin-
uation of 6-thioguanine therapy attenuates portal hyperten-1873-9946/$ - see front matter © 2010 European Crohn's and Colitis Org
doi:10.1016/j.crohns.2010.07.005sion, hence reducing the risk from this complication.7 As all
published series describe patients with clinically apparent
NRH (and thus late-stage disease), reversibility of early-stage
(pathohistological) disease with or without portal hyperten-
sion remains to be elucidated. In addition, a recent
retrospective study demonstrated that survival in patients
with NRH is highly variable and related to age and the
underlying disease process (in this series mainly malignant,
prothrombotic and rheumatological conditions), however not
to portal hypertension overall.8
Based on currently available literature, we conclude that
6-thioguanine should not be discarded as a potential rescue
drug when conventional thiopurines fail due to intractable
adverse events.References
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